Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancers. Led by a management team and advisors with world renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint Medicines has developed a platform that combines genomics with a novel small molecule library of kinase inhibitors, enabling Blueprint Medicines to rapidly discover potent and highly selective drugs against clear drivers of diseases. Founded in 2011, Blueprint Medicines is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/14 | $25,000,000 | Series B |
Biotechnology Value Fund Casdin Capital Nextech Invest Third Rock Ventures | undisclosed |
| 11/14/14 | $50,000,000 | Series C |
Biotechnology Value Fund Casdin Capital Cowen Investments Partner Fund Management Perceptive Advisors RA Capital Redmile Group Sabby Capital Third Rock Ventures Wellington Management Company | undisclosed |
